(19) World Intellectual Property **Organization** International Bureau



! [64] | 61] | 61] | 62] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63] | 63]

(43) International Publication Date 29 December 2004 (29.12.2004)

(10) International Publication Number WO 2004/113364 A1

(51) International Patent Classification⁷:

C07K 5/06

(21) International Application Number:

PCT/SE2004/001016

(22) International Filing Date:

23 June 2004 (23.06.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0301879-3

25 June 2003 (25.06.2003)

(71) Applicant (for all designated States except US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): GREHN, Marcus [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). MUSIL, Tibor [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). SJÖGREN, Magnus [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).
- (74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA. CH. CN. CO. CR. CU. CZ. DE. DK. DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, F1, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW PROCESS FOR THE PRODUCTION OF MELAGATRAN

(57) Abstract: There is provided a process for the production of melagatran, Formula (I) ex vivo, which process comprises the hydrolysis of a compound of Formula II, wherein R is C1-6 alkyl or a benzylic group, to form, in substantially salt-free form, an intermediate compound of formula II followed by reduction of that intermediate.

